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Summary    
A controlled clinical trial was undertaken in 247 patients
with newly diagnosed pulmonary tuberculosis to assess
the relative efficacies of a fully supervised twice-weekly
oral regimen of isoniazid plus PAS (para-aminosalicylic
acid) and a standard self-administered daily regimen
of the same drugs following an initial intensive phase of
two weeks of daily streptomycin, PAS, and isoniazid.
Among patients who had isoniazid-sensitive cultures init-
ially and who attended the clinic regularly the numbers
with a favourable bacteriological response at the end of
the year of chemotherapy were 79 (88%) out of 90 for the
twice-weekly regimen and 72 (87%) out of 83 for the daily
regimen; the numbers of patients with considerable
radiographic improvement were 54 (60%) and 53 (64%)
respectively. Complaints of vomiting or diarrhoea that
did not require a reduction of the PAS dosage were made
on one or two occasions by 23 (21 % ) out of 109 twice-weekly
and 25 (23%) out of 108 daily patients, and on at least three
occasions by 4 (4%) and 12 (11%) respectively. Finally,
al l  f ive patients who had chemotherapy changed on
account of hypersensitivityto PAS had been receiving
the daily regimen, as also had one patient who died of
agranulocytosis.
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Introduction
The efficacy in both the short and the long term of a twice-
weekly regimen of streptomycin plus high-dosage isoniazid in
the treatment of newly diagnosed pulmonary tuberculosis
ha  been well established by studies at this centre (Tuberculosis
Chemotherapy Centre, Madras, 1964, 1970; Ramakrishnan et
al., 1969). However, the regimen is not readily applicable in
rural areas of developing countries, where facilities for giving
injections are limited. In such situations fully supervised oral
intermittent regimens could be of great value. A controlled
study was therefore undertaken to compare the efficacy of a
twice-weekly oral regimen of PAS (para-aminosalicylic acid)
plu  high-dosage isoniazid with that of a daily regimen of PAS
plus conventional low-dosage isoniazid. PAS was chosen as the
substitute for streptomycin because it has been widely used for
many years and is readily available in developing countries.
Plan and Conduct of Study
The patients came from the poorest sections of the population
of the City of Madras and had reported at tuberculosis clinics
with symptoms. The criteria for admission to the study were
similar to those used in previous studies (see Tuberculosis
Chemotherapy Centre, Madras, 1960). In brief, the patients were
aged 12 years or more and had newly diagnosed tuberculosis
with at least two sputum cultures positive for Mycobacterium
tuberculosis (patients were provisionally admitted if they had two
or more positive sputum smears).
Chemotherapeutic Regimens.– For the first two weeks all the
patients attended the outpatient clinic daily and received, under
upervision, streptomycin 1 g, sodium PAS 6 g, and isoniazid
400 mg (incorporating pyridoxine 6 mg). For the next 50 weeks
the patients received on an outpatient basis either a twice-
weekly regimen (group 1) or a daily regimen (group 2). The
twice-weekly regimen comprised sodium PAS 0.2 g/kg body
weight plus isoniazid 15 mg/kg body weight, both drugs being
given at the same time in a single oral dose twice a week under th
close supervision of a nurse in the clinic (table I). In order to pre-
vent isoniazid neuropathy 6 mg of pyridoxine was incorporated in
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remaining 220 patients (111 in group 1, 109 in group 2) 203
(92%) had received no previous chemotherapy and 17 (8%)
had received up to two weeks of previous chemotherapy.
No patient was excluded on account of initial resistance to
PAS (for reasons see Selkon et al., 1960; Tuberculosis Chemo-
therapy Centre, Madras, 1960, 1966). Seven patients initially
had strains resistant to streptomycin but were not excluded
because the numbers in the two treatment groups were similar
(four in group 1, three in group 2) and the duration of strepto-
mycin therapy was only two weeks.
*Administered as cachets,  each contain ing 1.5 g of  sodium PAS,  and tablets of
isoniazid.
† Prcscribed as cachets, each containing 1.25 g of sodium PAS and 25 mg of isoniazid.
every dose of isoniazid (Tuberculosis Chemotherapy Centre,
Madras, 1963). The daily regimen comprised sodium PAS
0.2 g/kg body weight plus isoniazid 4.7 mg/kg body weight,
both drugs to be self-administered daily in two divided doses by
mouth (table I). The patients were allocated at random to the
two treatment groups at the time of admission to the study,
after stratification by the isoniazid inactivation rate and the
smear result of an overnight collection specimen of sputum.
General Management.– Progress was assessed mainly by
bacteriological examination of one clinic spot specimen and two
overnight collection specimens of sputum at monthly intervals,
and also by routine posteroanterior chest radiographs at one,
six, and 12 months; a radiograph was taken at other times if a
sputum smear was positive or if a physician deemed it necessary.
Patients on the daily regimen attended once a week to receive
a supply of drugs. The regularity of self-administration of
drugs was assessed by examining, by the sodium nitro-
prusside test (Rao et al., 1967), a urine specimen
produced at the clinic each week. In addition two visits were
made to the patient’s home each month and the stock of cachets
was counted; if the patient was available a urine specimen was
collected. If a patient on either the daily or the twice-weekly
regimen failed to attend on the appointed day a health visitor
visited the home the next day. No patient in this study had
collapse therapy or resection.
Bacteriological Procedures.-Sputum specimens were exam-
ined by fluorescence microscopy and cultured on Lowenstein-
Jensen medium. Positive cultures were tested for sensitivity to
isoniazid and streptomycin by standard methods (Tuberculosis
Chemotherapy Centre, Madras, 1960). Sensitivity to PAS was
determined by the proportion method (Canetti et al., 1969) and
resistance was defined as growth, on a medium containing 1 µg
of PAS per ml, of at least 1% of the bacterial population; this
criterion was chosen as it best distinguished sensitive strains
from those with acquired resistance in this study. Positive cultures
were tested for niacin production and for susceptibility to
sodium p-nitrobenzoate (Tsukamura and Tsukamura, 1964).
Rate of Inactivation of Isoniazid.– The concentration of
isoniazid in the serum four and a half hours after an intra-
muscular test dose of 3 mg/kg body weight was estimated
(Tuberculosis Chemotherapy Centre, Madras, 1970). Patients
with a concentration of 0.90 µg/ml or more were classified as
slow inactivators of isoniazid and those with a concentration
of 0.89 µg/ml or less as rapid inactivators.
Radiographic Assessment by Independent Assessor.– Th  extent
of cavitation and the total extent of the disease on admission
and the radiographic changes over the 12-month period were
assessed from posteroanterior chest radiographs, as described
previously (Tuberculosis Chemotherapy Centre, Madras, 1960),
by an independent assessor, Dr. K. V. Krishnaswami, who
was unaware of the treatment and clinical and bacterio-
logical findings for any individual patient.
Patients
Altogether 247 patients (122 in group 1, 125 in group 2) were
provisionally admitted to the study. It was subsequently
found that six failed to conform to the criteria for admission and
that 21 initially had strains resistant to isoniazid. Of the
Results
Of t e 220 patients 47 are excluded from the main analysis.
Three of these patients did not start the second phase of their
chemotherapy-two in group 1 died of tuberculosis on the 3rd
and 14th day respectively while they were receiving daily triple-
drug chemotherapy, and the third patient (in group 2) was
continued on the triple-drug chemotherapy beyond two weeks
on account of serious clinical deterioration. Of the remaining
44 patients 3 (1 in group 1, 2 in group 2) died from non-
tuberculous causes (myocardial infarction, agranulocytosis,
suicide) with negative sputum cultures, 5 (group 2) had their
chemotherapy changed on account of toxicity to PAS, 8 (5 in
group 1, 3 in group 2) took their discharge against medical
advi , and 28 (13 in group 1, 15 in group 2) missed a large
prop rtion of the allocated chemotherapy. Thus the main analysis
is based on 173 patients–90 in group 1 and 83 in group 2.
C O N D I T I O N  O N  A D M I S S I O N  T O  T R E A T M E N T
Th  mean age of the 173 patients was 32 years (95% range 17-
59 years) and the mean weight 38 kg (95% range 26-50 kg);
107 (62%) were males. Altogether 153 patients (88%) had
cavitated disease and a positive sputum smear and 70 (40%)
were rapid inactivators of isoniazid.
The two groups of patients were similar with respect to age,
sex, and weight (data not tabulated here), radiographic and
bacteriological condition on admission to treatment (table II),
and the proportion of rapid inactivators of isoniazid.
TABLE II – CONDITION ON ADMISSION TO TREATMENT
RESPONSE  TO  TREATMENT
Radiographically the response to treatment was similar in the
two series of patients. Thus 85 (94%) in group 1 and 80 (96%)
in group 2 showed improvement over the 12-month period,
including 54 (60%) and 53 (64%) with considerable improve-
ment. Cavitation, present initially in 80 group 1 and 77 group 2
patients on posteroanrerior radiography, had disappeared by
1 2  m o n t h s  i n  4 1  ( 5 1 % )  a n d  3 5  ( 4 5 % )  r e s p e c t i v e l y
and become less in 34 (42%) and 39 (51%) respectively.
Cavitation was observed at 12 months in three out of 10 group 1
and two of six group 2 patients in whom it had not been apparent
on admission.
The numbers of patients with a negative culture from a single
overnight collection specimen of sputum at monthly intervals
were similar in the two groups (table III). An isoniazid-resistant
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culture was obtained from 7 (8%) out of 88 group 1 and 3
(4%) out of 82 group 2 patients at three months, 10 (11%) and
5 (6%) respectively at six months, 10 (12%) and 5 (6%) at
nine months, and 9 (10%) and 8 (10%) at 12 months; none of
the differences was statistically significant. Out of 70 positive
cultures that we isolated between seven and 12 months from
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who received 97% of his chemotherapy, produced isoniazid-
sensitive cultures at 1, 2, 3, 10, and 11 months and negative
cultures at all the other months. The four group 2 patients
repeatedly produced isoniazid-sensitive cultures during treat-
ment. Although they had collected 80%, 91%, 98%, and
98% f their medicaments they were very irregular in self-
administering them, the proportions of negative urine test re-
sults being 44%, 71%, 73 %, and 90% respectively.
TABLE III- Patients with a Negative Culture from a Single Collection Specimen
of Sputum*
Months after  Start
of  Chemotherapy
Group 1 Pat ients Group 2 Pat ients
*Patients who, after the initial intensive phase of two weeks, died of tuberculosis
(1 in group 1, 1 in group 2) or had their chemotherapy changed on account of radio-
gra
 
phic or clinical deterioration (4 in group 1, 2 in group 2) are included throughout
and considered as having a positive culture at each month after the event.
the group 1 patients 61 (87%) were isoniazid-resistant, com-
pared with 36 (68%) out of 53 cultures isolated from the
patients in group 2.
The proportions of patients with a favourable response to
treatment at one year were also very similar in the two series
–namely, 88% and 87% (table IV) respectively. The unfavour-
TABLE IV – Response to Treatment, Assessed at One Year
Total with favourableresponse 79 88 72 87
Al l  cul tures negat ive at  3 or  more consecut ive
monthly examinations but a total of 2 or more
positive cultures at 10, 11, and 12 months
Cultures never all negative at 3 consecutive monthly
examinations
To ta l  w i th  un favou rab le  r e sponse    11  12  11  13
Grand total                                  90  100  83
*These patients were regarded as having a favourable response in view of experience
with similar groups of patients (Dawson et al., 1966;  Ramakr ishnan et al., 1969).
able responses included one patient in each group who died
of tuberculosis on the 29th and 27th days respectively and
four group 1 and two group 2 patients who had their chemo-
therapy changed, all between eight and 10 months, on account
of radiographic or clinical deterioration in the presence of
positive sputum; the radiographic deterioration was con-
firmed in all instances by an independent assessor, Dr. K. S.
Sanjivi.
Among the 20 failures (10 on each treatment regimen) who
had received at least one month of chemotherapy 15 (9 in
group 1, 6 in group 2) produced three or more isoniazid-resistant
cultures during treatment. In the remaining five patients (one in
group 1, four in group 2) there was no evidence that isoniazid
res i s tance  had  emerged .  Thus  the  g roup  1  pa t i en t ,
I N F L U E N C E  O F  I S O N I A Z I D  I N A C T I V A T I O N  R A T E  O N  R E S P O N S E  T O
TREATMENT
The condition on admission to treatment was broadly similar
for the rapid and slow inactivators of isoniazid in both treatment
series. There was a suggestion that the response to the twice-
weekly regimen was better in slow inactivators than in rapid
inactivators, the numbers with a favourable response at one
year being 48 (92%) and 31 (82%) respectively (P = 0.2). The
corresponding numbers for those on the daily regimen were
45(88 %) and 27 (84%) (P > 0.2).
PROGNOST IC  IMPORTANCE  OF  VAR IOUS  FACTORS
In patients on the twice-weekly regimen the response to treat-
ment was greatly influenced by the initial bacterial content in
the sputum and probably by the extent of disease and the extent
of cavitation on admission. Thus of the 54 patients with a three-
plus or two-plus smear result in an overnight collection specimen
of putum 11 (20%) had an unfavourable response at one year,
compared with none of the 36 patients with a one-plus or
negat ive smear  resu l t  (P  < 0.01) .  The corresponding
response rates for the 64 patients with extensive or moderate
cavitation and for the 26 with slight or no cavitation
were 10 (16%) and 1 (4%) (P = 0.1), and for the 70 patients
with gross, extensive, or moderate disease and for the 20 with
limited or slight disease 10 (14%) and 1 (5%) (P = 0.2). In
patients on the daily regimen there was no evidence that any
of these factors influenced the response.
Sex and age were of no prognostic importance in either series.
PAS-SENS IT IV ITY  TEST  RESULTS
At least one PAS-resistant culture was obtained before treatment
from 21 of the 173 patients (9 in group 1, 12 in group 2); 5
(24%) (2 in group 1, 3 in group 2) had an unfavourable res-
ponse to treatment, as compared with 17 (11%) (9 in group 1,
8 in group 2) out of 152 patients (81 in group 1, 71 in group
2) who had PAS-sensitive cultures on admission to treatment
(P = 0.1).
Eight patients on the twice-weekly regimen and six on the
daily regimen had PAS-sensitive cultures before treat-
ment and either produced positive cultures at 10, 11, and 12
months or had chemotherapy changed during the year on
account of deterioration. In four patients in each group at
least two of the last three cultures tested were PAS-resistant.
A C C E P T A B I L I T Y  O F  R E G I M E N S
Eight patients (five in group 1, three in group 2) took their
discharge against medical advice for reasons not connected
with the drugs, four (three in group 1, one in group 2) refused
further treatment, and four moved out of Madras. A further
28 patients (13 in group 1, 15 in group 2) were known defin-
it ly o have missed more than 25% of their chemotherapy in
the first six months or over the whole year, or had received no
chemotherapy for a continuous period of more than four
weeks; in 10 (4 in group 1, 6 in group 2) this was largely due
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to complications such as hypersensitivity reactions or jaundice.
All the above 36 patients are excluded from the main analysis.
Of 89 patients on the twice-weekly regimen who are in-
c luded  i n  the  ma in  ana lys i s  ( exc lud ing  1  who  d ied
in the fifth week) 77 (87%) received at least 90%
of their allocated chemotherapy. Of these, 9 (12%) had an
unfavourable response compared with 1 (8%) of 12 who
received less than 90% of their chemotherapy. There was no
evidence that any of the patients supplemented their twice-
weekly chemotherapy with isoniazid from other sources, for out
of 4,569 urine specimens collected immediately before the
administration of a dose of medicaments 4,526 (99%) yielded
negative results by the acetylisoniazid test of Eidus and Hamilton
(1964).
At least 90% of the allocated chemotherapy was collected by
76 (93%) of 82 patients on the daily regimen included in the
ma in  ana lys i s  ( exc lud ing  1  who  d ied  i n  the  f ou r th
week). S o m e  o f  t h e  p a t i e n t s ,  h o w e v e r ,  w e r e  v e r y
irregular in self-administering their medicaments, and this had
therapeutic implications. Thus an unfavourable response was
observed in seven out of 14 (50%), two out of 25 (8%), and one
out of 43 patients (2%) who had negative urine test results on
50% or more, 25-49%, and less than 25% of the occasions
respectively-a significant trend (P = 10-5) .
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second phase. Patients were not questioned to elicit symptoms
of drug toxicity; however, every spontaneous complaint was
followed by careful questioning by a physician and then recorded.
Findings indicating toxicity to PAS are presented in table V.
Agranulocytosis.– One patient (in group 2) developed
agranulocytosis (total leucocytes 1,600/mm3, poly orphonuclear
leucocytes 8%) with anaemia (haemoglobin 7.2 g/ 100 ml,
packed cell volume 35%), high fever, and delerium in the third
month; the antituberculosis drugs were stopped immediately
and the patient was admitted to hospital, but he died seven days
later.
Hyp rsensitivityt o  P A S . * –  One pat ient  in  group 19
developed cutaneous hypersensitivity to PAS compared
with 10 patients in group 2 (P < 0.01). Of these 11 patients
three (all in group 2) developed jaundice at the time, includ-
ing on  who had a hypersensitivity reaction to isoniazid also.
The group 1 patient developed the cutaneous hypersensitivity
r action in the fourth month, was desensitized, and resumed the
allocated treatment. Of the 10 group 2 patients 8 developed
th  re ction in the second month and 2 in the third month. Six
of thes  10 patients were desensitized and resumed the daily
regimen (one had his chemotherapy changed subsequently on
account of severe vomiting and recurrence of the cutaneous
hypersensitivity); the remaining four had their chemotherapy
changed, desensitization not having been attempted on account
of the severity of the hypersensitivity reaction or other clinical
complications.
Gastrointestinal Complaints.– Chemotherapy had to be
changed in the fourth month in one patient (group 2) on
account of severe vomiting and cutaneous hypersensitivity to
PAS (see above). Complaints of vomiting or diarrhoea that did
not require a reduction of the PAS dosage were made on one
occasion by 15 (14%) of the group 1 patients and 21 (20%) of
the group 2 patients, on two occasions by 8 (7%) and 4 (4%)
respectively, and on three or more occasions by 4 (4%) and 12
(11%) respectively; the contrast between the two series was
significant (P = 0.04).
Jaundice.– In addition to the three patients (all in group 2)
mentioned above three (two in group 1, one in group 2) de-
veloped jaundice in the fourth, fifth, and third months respec-
tively. PAS was withheld until the jaundice cleared, which
was five, five, and two weeks later; when PAS was reintro-
duced jaundice did not reappear.
Neurological Complaints Attributed to Isoniazid.– One patient
(in group 1, slow inactivator of isoniazid) had a single attack
of convulsions in the ninth month, two and a half hours after
the administration of a dose of chemotherapy. Symptoms sug-
gestive of peripheral neuropathy were reported on two or
more occasions by three group 1 patients (two slow, one rapid)
and six group 2 patients (five slow, one rapid), including one
patient (group 2, slow) who had physical signs. All 10 patients
continued on their allocated chemotherapy.
D I S E A S E  S T A T U S  A T  O N E  Y E A R  I N  D I S C H A R G E D  A N D  I R R E G U L A R
P A T I E N T S
Of the eight patients who took their discharge against medical
adv i ce  one  (g roup  2 )  d ied  i n  he r  v i l l age  (p resum-
ably of tuberculosis) and three (all in group 1) produced
at least one positive culture between 10 and 12 months;
all four were culture-positive at the time of their discharge
in the second, third, third, and fourth months respectively.
Three patients (one in group 1, two in group 2) produced only
negative cultures between 10 and 12 months; all of them
were culture-negative at the time of discharge and none received
chemotherapy subsequently from any source. No specimens
could be collected between 10 and 12 months for the eighth
patient (in group 1).
With regard to the 28 patients who missed large proportions of
their allocated chemotherapy, nine out of 13 on the twice-
weekly regimen (69%) and four out of 15 on the daily regimen
(27%) had a favourable response at one year (P = 0.06).
There proportions are much smaller than those in the patients
included in the main analysis–namely, 79 (88%) out of 90
on the twice-weekly regimen (P = 0.09) and 72 (87%) out of
83 on the daily regimen (P < 10-5) .
When the above 36 patients are included the proportions with
a favourable disease status at one year are 89 out of 107 (83%)
on the twice-weekly regimen and 78 out of 101 (77%) on the
daily regimen (P > 0.2).
DRUG TOXIC ITY
The findings below are based on the 217 patients (109 in group 1,
108 in group 2) who were eligible for the study and who started
the second phase of their chemotherapy, and pertain to the
TABLE v-Toxicity to PAS in the 217 Patients who started Second Phase f
Chemotherapy
Death due to agranulocytosis . . . .
Hypersensitivity to PAS
At least 3 complaints of vomiting or diarrhoea: :
Jaundice  .
Discussion
The main advantage of intermittent chemotherapy over daily
chemotherapy is that it is practicable to administer it under
full supervision and thereby eliminate concealed irregularity–
a major problem with self-administered daily regimens. Further-
more, for any given combination of drugs intermittent regimens
are usually less toxic and invariably less expensive. Previous
studies from this centre showed that a twice-weekly regimen
consisting of streptomycin injections and high-dosage oral
isoniazid, without an initial intensive phase, was at least as
effective, in both the short and the long term, as a daily regimen
of isoniazid plus PAS in conventional dosage (Tuberculosis
Total . . . . . . . 7 (6%) 23† (21%)
* Of these, 5 had to have their chemotherapy changed.
† Some patients appear in more than one category.
*One patient developed hypersensitivity to PAS manifested by urticaria and
jaundice in the first phase of chemotherapy-that is, when he was receiving
6 g of the drug daily. He was desensitized and subsequently received the
allocated twice-weekly regimen.
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Chemotherapy Centre, Madras, 1964; Ramakrishnan et al.,
1969).
The findings in this study with the fully oral twice-weekly
regimen of isoniazid plus PAS are encouraging. Thus, at the end
of one year of chemotherapy 79 (88%) of the 90 patients who
received this regimen had a favourable bacteriological response,
compared with 72 (87%) of the 83 patients who received a
standard daily regimen of isoniazid plus PAS; 54 (60%) and
53 (64%) respectively showed considerable radiographic
improvement. Chemotherapy was changed on account of
hypersensitivity to PAS in five of the daily patients, compared
with none of the twice-weekly patients, and the incidence of
gastrointestinal complaints was lower in the latter. Thus the
less expensive twice-weekly regimen, in which the total weekly
dosage of PAS was less than a third of that in the daily regimen,
was better tolerated. This finding is similar to the experience of
Tempel et al. (1950) with streptomycin-namely, toxicity in
38 out of 66 patients (58%) who received daily streptomycin
1 g or 2 g for four months, compared with only five out of 97
patients (5%) who received the same dose twice a week.
The incidence of hypersensitivity to PAS with the daily
regimen was 9% in the present study and 3%, 3%, 4%, and
6% in the earlier studies at this centre (Tuberculosis Chemo-
therapy Centre, Madras, 1959, 1960, 1964, 1966), the mean for
all studies, based on 532 patients, being 4.7%. The incidence
was 1 (0.9%) out of 109 with the twice-weekly regimen in this
study, and 1 (0.6%) out of 178 with a once-weekly regimen of
sodium PAS (6 g), isoniazid, and streptomycin in an earlier
study (Tuberculosis Chemotherapy Centre, Madras, 1973). The
tendency for a lower incidence with an increase in the interval
between successive doses was significant (P = 0.001). This
finding is different from the experience with rifampicin,
toxicity to which occurs, possibly due to an immunological
mechanism, more frequently during intermittent administration
than during daily administration of the drug (Mary Aquinas
et al., 1972).
Although the twice-weekly and daily regimens were of similar
efficacy in the present study there is reason to believe that the
former regimen would have been marginally less effective if
the regularity in drug intake had been equal for the two regimens.
In the event there was greater irregularity with the daily regimen,
and the association between regularity and response was strong
in the case of this regimen only. Next, the proportion of failures
with isoniazid-resistant cultures was higher with the twice-
weekly regimen. Finally, the efficacy of the twice-weekly regimen,
unlike that of the daily regimen, was much influenced by the
† At this centre 32 guinea-pigs were infected intramuscularly with 0.1 mg
(moist weight) of the H37Rv strain of M. tuberculosis. From the 10th day
PAS 0.2 g/kg was administered by gastric intubation daily to eight animals,
on alternate days to eight animals, and once in four days to eight animals;
the remaining eight animals were left untreated as controls. At the end of
six weeks of treatment the root index of disease was determined by employ-
ing the procedures described by Mitchison et al. (1961). The mean root
indices were 0.88, 0.98, and 1.03 for guinea-pigs that had received treatment
daily; alternate days, and once in four days, respectively, and 1.32 for the
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size of the initial bacterial population, probably by the extent
of disease and the extent of cavitation on admission, and
probably also by the rate of inactivation of isoniazid. These
findings indicate that if taken regularly a given dose of PAS
is slig tly less effective twice-weekly than daily, in keeping with
earlier xperimental work (Karlson and Carr, 1958; P. Venka-
taram n, S. Subbammal, and S. P. Tripathy, unpublished
dat t). It would therefore be valuable to strengthen the twice-
weekly regimen. This could be done by extending the initial
period of triple-drug chemotherapy from two weeks to four
weeks or more in view of the evidence that an initial intensive
phase greatly enhances the therapeutic efficacy (Medical
Re earch Council, 1962; East African/British Medical Research
Council, 1970; Tuberculosis Chemotherapy Centre, Madras,
1970; International Union Against Tuberculosis, 1970).
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